Index. At a Glance. Letter to Shareholders. Corporate Governance. Compensation Report. Financial Statements

Size: px
Start display at page:

Download "Index. At a Glance. Letter to Shareholders. Corporate Governance. Compensation Report. Financial Statements 2014 50."

Transcription

1 ANNUAL REPORT 2014

2

3 Index 3 At a Glance 6 Letter to Shareholders 9 Corporate Governance 39 Compensation Report 49 Financial Statements Financial performance and results of operations (IFRS) 54 Consolidated financial statements and notes (IFRS) Statutory financial statements and notes Glossary Legal Disclaimer

4 Cytos Biotechnology Ltd At a Glance 4

5 Cytos Biotechnology Ltd is a Swiss public biopharmaceutical company domiciled in Schlieren (Zürich), Switzerland and is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Contact addresses Stock exchange information Listing SIX Swiss Exchange Registered shares SIX:CYTN; Swiss Security No.: Convertible Bond due in 2015 SIX:CYT07; Swiss Security No.: Cytos Biotechnology Ltd Wagistrasse Schlieren (Zurich) Switzerland Phone Fax Media relations Christian Itin, PhD Chairman & Chief Executive Officer Phone Fax Share register Aktienregister Cytos Biotechnology Ltd c/o Nimbus AG Investor relations Postfach Harry Welten, MBA 8866 Ziegelbrücke Chief Financial Officer Switzerland Phone Phone Fax Fax Cytos on the internet Annual and quarterly reports on the website Investor Relations Reports & Presentations 5

6 Letter to Shareholders 6

7 Dear Shareholder We have lived through a challenging 2014 which was marked by the negative outcome of the P2b clinical study with CYT003 in April 2014 and the necessary restructuring of the company in the wake of it. The fundamental issue the company was dealing with was the high level of debt from the 2007 bond and the additional debt that the company had to accept in the 2012 refinancing. While the immediate actions were focused on minimizing cash out flow and preservation of the key assets of the company, the later part of the year and in particular this year have been directed at addressing the debt of the company and creating upside from the company s asset base. With that look back let us update you on the substantial progress made since the beginning of On January 6, 2015, an exclusive license agreement was executed with OnCore Biopharma, Inc. (now merged with Tekmira, a public listed company on Nasdaq) granting access to Cytos clinically validated virus like particle platform for the use in the treatment and prevention of hepatitis B viral infections. Cytos also granted an option to OnCore Bio pharma for the treatment of further viral diseases other than influenza. The agreement will become effective with the achievement of certain closing conditions, including a successful debt restructuring of Cytos. For the first product in each of six possible product categories in the field of Hepatitis B that may be developed under the agreement, Cytos may receive up to USD 67 million in development milestones, or a maximum of USD 402 million if one product in each product category is developed. In addition, Cytos is eligible to receive commercial milestone payments of up to USD 120 million upon achievement of certain sales levels, and up to double digit royalties on net sales from any successfully developed product. In our continued effort to eliminate Cytos debt burden, we have achieved key steps to date. First, the bondholders meeting held in January 2015 approved the conversion of their bonds into shares with an 84% majority of all bond holders voting in favor of the conversion. The second step required was an approval by the Higher Court of the Canton of Zurich which was obtained in March The appeal period with the Supreme Court will end by the end of April 2015 and unless an appeal is filed the application becomes final and binding soon thereafter. In March 2015, the shareholders have also approved the capital needed to create the shares used for the exchange of the bonds. As a consequence, the bonds can be exchanged into shares in the first half of May 2015 if no appeal is filed. With this conversion, about half of the overall debt will be eliminated. With regards to the second half of the debt: the non subordinated portion of CHF 14.2 million was repaid at maturity in February, Further, CHF 2 million of the claims of the loan note holders were eliminated by converting the same amount into convertible bonds. As a result, subordinated residual claims of CHF 6 million remain outstanding. We are currently in discussions with the loan note holders regarding the settlement of theses residual claims. As soon as a final settlement agreement has been signed, we will inform you accordingly. Such an agreement would support the continued going concern of Cytos and in turn would allow Cytos to potentially acquire a privately held company with intact projects and/or commercial products using stock. Such a combined company would have an intact asset base and potential for value creation for shareholders. We would like to thank you, our creditors and our employees for your trust and support without which we would not have been able to advance thus far. Best regards Cytos Biotechnology Ltd. Christian Itin, PhD Chairman & Chief Executive Officer Harry Welten, MBA Chief Financial Officer 7

8

9 Corporate Governance 9

10 Cytos Biotechnology Ltd Corporate Governance The Articles of Association (the Articles ) of Cytos Biotechnology Ltd can be viewed at under Investor Relations Corporate Governance. Link: The information published below conforms to the Corporate Governance Directive ( DCG ) of the SIX Swiss Exchange ( SIX ). The numbering of the subsections was made on the basis of the DCG. Group structure and shareholders (DCG 1) Group structure (DCG 1.1) With regard to its activities in biotechnology, the board of directors ( Board of Directors ) and the executive board ( Executive Board ) review the financial performance on an aggregate basis and manage the operations of Cytos Biotechnology Ltd (the Company ) as a single operating entity. Accordingly, the Company operates in one segment, which is the business of development and commercialization of products for human health care. Cytos Biotechnology Ltd, Schlieren, Switzerland, is listed according to the Main Standard on the SIX Swiss Exchange, Zurich, Switzerland. Security number ISIN CH Ticker symbol CYTN Market capitalization on December 31, 2014 CHF 7.02 million The Company is a corporation established under Swiss law with its registered office in Schlieren, Switzerland. As at December 31, 2014 the group consists of the parent company Cytos Biotechnology Ltd and two non-listed companies: Name Proteome Therapeutics GmbH, Singen, Germany BioSupport AG in Liquidation, Schlieren, Switzerland* Share capital (in thousands) Shareholding EUR 25 CHF % 33% * BioSupport AG will be liquidated in 2015 since its services are no longer required by Cytos. Preliminary excess cash of TCHF 80 has been paid to Cytos in 2014 and is accounted as accrued expenses. 10

11 Cytos Biotechnology Ltd Corporate Governance Significant shareholders (DCG 1.2) According to disclosure notifications filed with the Company to the SIX Swiss Exchange, each of the following shareholders held more than 3% of the share capital of the Company as of December 31, 2014: A group consisting of: venbio Global Strategic Fund L.P., Grand Cayman, Cayman Islands ultimately jointly controlled by: Corey Goodman, Marshall, CA, USA Paul Brooke, New York, NY, USA Robert Adelman, Hillsborough, CA, USA (Kurt von Emster, a former partner, and Paul Brooke also hold certain stock options on shares of Cytos Biotechnology Ltd) Amgen Investments Ltd., Hamilton, Bermuda ultimately controlled by: Amgen Inc., Wilmington, Delaware, USA (a publicly listed company and the ultimate parent company of the Amgen group of companies) Abingworth Bioventures V L.P., London, UK voting rights are exercised by Abingworth Bioventures V L.P. s investment manager: Abingworth LLP, London, UK (certain stock options on shares in the Company are held for the account of Abingworth LLP as the investment manager of Abingworth Bioventures V L.P., by Joseph Anderson, Surrey, UK) Abingworth Bioequities Master Fund Limited, Ugland House, Grand Cayman, Cayman Islands ultimately controlled by: Abingworth LLP, London, UK (together with Abingworth Bioventures V L.P., the Abingworth Funds ) Aisling Capital III, LP, New York, NY, USA ultimately controlled by: Aisling Capital Partners III, LLC, New York, NY, USA holds 0 voting shares (registered shares) with a current proportion of voting rights of 0%. holds 67.81% proportion of voting rights* based on financial instruments. HERCULIS Partners «Aries» Fund (IFM Independent Fund Management AG) Austrasse 9, 9490 Vaduz (Liechtenstein) holds voting shares (registered shares) with a current proportion of voting rights of 3.53%. * The proportion of voting rights based on financial instruments is calculated pursuant to Art. 12 para. 2 of the Ordinance of the Swiss Financial Market Supervisory Authority on Stock Exchanges and Securities Trading [Verordnung der Eidgenössischen Finanzmarktaufsicht über die Börsen und den Effektenhandel (BEHV-FINMA)] on the basis of the entry in the commercial register. 11

12 Cytos Biotechnology Ltd Corporate Governance Information on disclosure notifications during the year under review, concerning the significant shareholders and the financial instruments in particular may be found on the SIX Exchange platform on the following page: The Company has not entered into any agreement with any shareholder regarding the voting or holding of shares in the Company. To the knowledge of the Company, no shareholders are linked by any shareholder agreement. Cross-shareholdings (DCG 1.3) There are no cross-shareholdings. Capital structure as of December 31, 2014 (DCG 2) Excerpt from the Articles of Association of Cytos Biotechnology Ltd as of April 3, 2014 Capital (DCG 2.1) The share capital of Cytos Biotechnology Ltd is CHF 3,052,527.60, fully paid up and divided into 30,525,276 registered shares with a nominal value of CHF 0.10 each, according to the Commercial Register of the Canton of Zurich. Conditional capital (DCG 2.2) Article 4b: The share capital may be increased by the maximum amount of CHF 1,120, by issuing up to 11,205,715 fully paid up registered shares with a nominal value of CHF 0.10 each. The issue of registered shares by exercising conversion and/or Option rights and any other transfer of shares is subject to the transfer restrictions pursuant to Article 5 ofthe Articles of Association. Upon exercising the option rights granted to them, employees of the Company and its subsidiaries as well as members of the Board of Directors or the Scientific Advisory Board will receive a maximum of 273,273 of these registered shares. The issue price as well as the conditions for the allocation and exercise of the employee options was, or for new employee options will be specified by the Board of Directors in separate Rules. The Company s shareholders are not entitled to subscribe to such employee options, unless they fulfill the conditions of the Rules in their function as employees, members ofthe Board of Directors or the Scientific Advisory Board. Additional registered shares will be issued upon exercise of the 350,000 option rights that were given to an investor pursuant to the Option Agreement dated March 20, 2012 as compensation for its expenses in connection with the placement of the majority of the shares issued as part of the capital increase resoived for at the General Meeting dated April 20, The options have an exercise term of five years following entry of this provision of the Articies of Association in the commercial register and an exercise price (subject to any adjustments within the scope of antidilution protection pursuant to the Option Agreement) of CHF 2.244* (hereinafter referred to as the 2012 OPTIONS ). *Adjusted to CHF 2.13 following the application of the anti-dilution clause in connection with the 2013 financing. 12

13 Cytos Biotechnology Ltd Corporate Governance All of the rest of these registered shares not used or reserved for the Option rights of employees pursuant to paragraph 2 or for the Option rights of an investor under paragraph 3 will be issued upon exercise of: a) conversion rights granted to the bond creditors of the outstanding convertible bond (Swiss Security Number ) (hereinafter referred to as the CONVERTIBLE BONDS ); as well as b) conversion rights that were granted to investors as part of the 9% convertible loan notes with a total amount of CHF 13,250,000 and with a maturity date on February 10, 2015 pursuant to the Convertible Loan Note Agreement dated March 20, 2012, and which provide for, among other things, a conversion during the conversion term, which starts upon entry of this provision of the Articles of Association in the commercial register and ends on January 30, 2015, at a conversion price (subject to any adjustments within the scope of anti-dilution protection pursuant to the Convertible Loan Note Agreement) of CHF 2.244* (hereinafter referred to as the CONVERTIBLE LOAN NOTES ). *Adjusted to CHF 2.13 following the application of the anti-dilution clause in connection with the 2013 financing. In addition, all of the rest of these registered shares not issued for the Option rights of employees pursuant to paragraph 2, the Option rights of an investor under paragraph 3, the CONVERTIBLE BONDS or the CONVERTIBLE LOAN NOTES under paragraph 4 may be used in conjunction with the exercise of the 2012 WARRANTS. The 2012 WARRANTS are warrants that are issued pursuant to the Warrant Agreement dated March 20, 2012 and that entitle each warrant holder to subscribe to a new registered share of the Company. These warrants may be exercised during an exercise term of four years following entry of this provision of the Articies of Association in the commercial register, and the exercise price (subject to any adjustments within the scope of anti-dilution protection pursuant to the Warrant Agreement) is CHF 2.244* per warrant. *Adjusted to CHF 2.13 following the application of the anti-dilution clause in connection with the 2013 financing. The Board of Directors shall determine the issue conditions for the CONVERTIBLE BONDS, CONVERTIBLE LOAN NOTES, 2012 WARRANTS and 2012 OPTIONS (provided that such is not already stipulated out in paragraphs 3 to 5 of the present Article 4b). The subscription rights of shareholders with regard to the shares that are issued in connection (i) with the exercise of the rights associated with the CONVERTIBLE BONDS or the CONVERTIBLE LOAN NOTES, or (ii) with the exercise of the 2012 OPTIONS or the 2012 WARRANTS, are excluded. The shareholders neither have a right to subscribe to the 2012 OPTIONS nor the 2012 WARRANTS. Furthermore, the preferential subscription right of existing shareholders is excluded for the CONVERTIBLE BONDS and the CONVERTIBLE LOAN NOTES. Article 4h: The Company s share capital shall be increased by an amount not exceeding CHF 153, through the issue of a maximum of 1,535,637 registered shares, to be fully paid in, with a nominal value of CHF 0.10 per share through (i) the voluntary or compulsory exercise of conversion rights and/or warrants granted or to be granted in connection with bonds or other financial market instruments or loans of the Company, or any of its group companies, that allow for conversion into shares of the Company (equity-related financial instruments) or (ii) the exercise of options granted to all shareholders (shareholder options). For equity related instruments the shareholders pre-emptive rights are excluded. Holders of such equity-related financial instruments are entitled to subscribe to the new shares. The Board of Directors fixes the conversion warrant conditions. Shareholder options must be allocated to all shareholders pro rata to their shareholding. The Board of Directors fixes the exercise conditions. 13

14 Cytos Biotechnology Ltd Corporate Governance The acquisition of shares through the exercise of conversion rights and/or warrants and/or shareholder options and any subsequent transfer of the shares are subject to the restrictions set out under Art. 5 of these Articies of Association. The Board of Directors is authorized to exclude shareholders preferential subscription rights in relation to equity-related financial instruments when such equity-related financial instruments are issued provided these instruments are being issued to finance or refinance the acquisition of companies, parts of companies, participations or new investment projects, and/or if the instruments are issued on the national or international capital markets (including private placements). If shareholders preferential subscription rights are restricted or excluded for such equity-related financial instruments: (i) these equity-related financial instruments must be issued at prevailing market conditions, (ii) the issue price of the new shares must be set at market conditions taking due account of the stock market price of the shares and/or comparable instruments priced by the market, and (iii) the conversion rights may be exercised for a maximum of 12 years and the warrants may be exercised for a maximum of 7 years from the relevant issue date. Article 4i: The share capital of the Company increases in the nominal value of up to CHF 252, by issuance of up to CHF 2,521,286 fully paid-in registered Shares with a nominal value of CHF 0.10 per share, subject to the exercise of options granted by the Company to employees of the Company or its subsidiaries, persons of a comparable position and Board members. The pre-emptive rights of the shareholders shall be excluded. The conditions of the grant of the options, as the amount of the issue of the shares, the time of the entitlement for dividends as well as the kind of contribution, shall be determined by the Board of Directors in the form of special rules (Stock Option Plans). The further transfer of the registered Shares acquired by the exercise of the conversion or options rights under this article shall be subject to the restrictions of Article 5 of these Articles of Association. Authorized capital (DCG 2.2) Article 4c: The Board of Directors is authorized to increase the share capital at any time until June 27, 2015 by an amount not exceeding CHF 1,120, by issuing up to 11,205,715 fully paid up registered shares with a nominal value of CHF 0.10 each. Increases by way of an underwriting by a bank, a bank consortium or a third party subject to an exclusion of the pre-emptive rights or any preferential subscription rights according to paragraph 3 of the present Article 4c, a subsequent offer to the shareholders and increases in partial amounts are allowed. In each case, the issue price, the date for entitlement to dividends and the type of contribution shall be determined by the Board of Directors, provided that nothing to the contrary is stipulated in the present Article 4c. The newly issued registered shares shall be subject to the transfer restrictions foreseen in article 5 of the Articies of Association. 14

15 Cytos Biotechnology Ltd Corporate Governance The Board of Directors is authorized to issue shares according to Paragraph 1 of the present Article 4c as (i) base values of 12,700, WARRANTS (as defined in Article 4b Paragraph 5), whereby the Board of Directors determines the issue conditions of the 2012 WARRANTS (provided that they are not already stipulated in Article 4b Paragraph 5), or (ii) to use said shares in a maximum amount of CHF 60, for employees, members of the Board of Directors and consultants of the Company and its subsidiaries who have exercised the Option rights granted to them, whereby the issue amount and the conditions für allocating and exercising the employee options by the Board of Directors are stipulated in separate Rules. The subscription rights of shareholders with regard to the shares that are issued in connection with the exercise of the rights associated with the 2012 WARRANTS or the employee options are excluded. The shareholders do not have a right to subscribe to the 2012 WARRANTS. Article 4g: The Board of Directors is authorized, at any time until December 30, 2015, to increase the share capital by a maximum of CHF 405, through the issuance of a maximum of 4,056,923 registered shares, to be fully paid up, with a nominal value of CHF 0.10 per share. Increases by underwriting as well as partial increases are permissible. The issue price, the time of dividend entitlement, and the type of contribution will be determined by the Board of Directors. Upon acquisition, the new shares will be subject to the transfer restrictions pursuant to Art. 5 of the Articles of Association. The Board of Directors is authorized to exclude shareholders pre-emptive rights if the new registered shares are used for (a) the allocation of shares to existing shareholders in case the subscription of shares in a rights offering exceed the number of shares available; (b) the acquisition of companies, segments of companies or participations through an exchange of shares; (c) for financing/refinancing the acquisition of companies, segments of companies or participations, or (d) investment plans and/or instruments that are issued on the national or international capital markets or for raising capital in a fast and flexible manner (including private placements) and that could probably not be achieved without the exclusion of the legal pre-emptive rights of shareholders. If commitments to service convertible bonds or loans or bonds with warrants are assumed in connection with company take-overs or investment plans, the Board of Directors is authorized, for the purpose of fulfilling delivery commitments under such bonds, to issue new shares excluding the pre-emptive rights of shareholders. Registered shares for which pre-emptive rights have been granted but not exercised, are to be used in the best interests of the Company or sold on the market at market conditions. The full text of the Articles of Association is available on the Company s website under the following link: Changes in capital (DCG 2.3) For further information on the changes in the capital structure in 2014, please see note 17 of the detailed consolidated financial statements. 15

16 Cytos Biotechnology Ltd Corporate Governance Description of changes in capital that have taken place within the last three financial years: Consolidated Statement of Change in Shareholders Equity1 in TCHF (except for share information) December 31, 2011 Adjustment IAS 19, revised Number Share Additional of shares capital paid-in capital 5,270, ,938 Other2 Total (224,145) (554) (11,680) (554) Total comprehensive loss (9,044) (9,044) Convertible Bond/-loan notes: equity component 4,260 4,260 Partial repurchase of convertible bonds (127) (127) Convertible Bond/-loan notes: deferred tax (932) (932) Convertible Bond/-loan notes: costs (127) (127) Issuance of share capital 14,900,232 1,490 26,682 28,172 Share capital issuance costs (1,190) (1,190) Treasury shares 2,241, (224) Share-based compensation December 31, 2012 restated 22,411,431 2, ,299 (230,893) 9,647 Total comprehensive loss (30,943) (30,943) Convertible Bond/-loan notes: equity component Issuance of share capital 8,113, ,530 24,342 Issuance of share capital from Treasury shares 80, Use of Treasury shares (80,975) (8) 8 Share capital issuance costs (1,100) (1,100) Share-based compensation 1,309 1,309 Reclassification 134 (134) December 31, ,525,276 3, ,428 (261,251) 4,230 Total comprehensive loss (34,388) (34,388) Issuance of share capital from Treasury shares 55, Use of Treasury shares (55,520) (6) 6 Share based compensation 3,748 3,748 December 31, ,525,276 3, ,360 (295,633) (26,220) 1) For further details see Consolidated Statements of Change in Shareholders Equity and Note 17, Shareholders equity, to the consolidated financial statements. 2) Including: legal reserves, Treasury shares, accumulated deficit, cumulative translation adjustment, equity component of the convertible bonds outstanding and cumulative pension adjustments. 16

17 Cytos Biotechnology Ltd Corporate Governance Shares and participation certificates (DCG 2.4) The Company has only one class of shares, i.e. registered shares with a nominal value of CHF 0.10 each. Each share is fully paid up and carries one vote and equal dividend rights with no privileges. The Company has no outstanding participation certificates. The Company s shares are not certified. Shareholders are not entitled to request printing and delivery of share certificates; however, any shareholder may at any time request the Company to issue a confirmation of its shareholding. Profit-sharing certificates (DCG 2.5) The Company has not issued any profit-sharing certificates. Limitations on transferability and nominee registrations (DCG 2.6) If buyers of registered shares explicitly declare in the request for registration that they have bought the registered shares in their own name and for their own account, they shall be registered in the share register as shareholders with voting rights. Article 5 of the Articles furthermore provides that shareholders may register their shares in the name of a nominee ( Nominee ) and may exercise their voting rights by giving instructions to the Nominee to vote on their behalf. However, a Nominee holding more than 3% of the Company s share capital may be registered as a Nominee for shareholders with voting rights only if the Nominee discloses the identity of those ultimate beneficial owners of shares claiming 0.5% or more of the Company s share capital. To remove or amend the above mentioned limitations on transferability and nominee registrations, the approval of (i) at least two-thirds of the votes represented and (ii) the majority of the represented share capital at the respective shareholders meeting would be required. Convertible bonds and options (DCG 2.7) In February 2007, the Company issued 2.875% p.a. convertible bonds ( Convertible Bond ) with a nominal value of CHF 70 million. The Convertible Bond was initially due for repayment on February 20, However, following a resolution of the bondholders on November 10, 2011, which became legally binding on March 13, 2012, half of the then outstanding nominal value was repaid at par. The repayment for the remaining half as well as the payment of any interest since February 21, 2011 has been deferred to February 20, 2015 with a repayment at 150% of par. Also, the coupon has been increased from 2.875% p.a. to 5.75% p.a. Furthermore, the conversion price has been reduced to CHF In connection with the rights offering in November 2013, the conversion price has been further reduced to CHF 7.32 per share due to the anti-dilution clause, representing a conversion ratio of registered shares of the Company per Convertible Bond of CHF 2,500. CHF 179, representing 1,798,839 shares of the Company s conditional and authorized capital can serve as underlying shares for the extended outstanding convertible bonds during the extended maturity. The Convertible Bond is listed on the SIX Swiss Exchange under the symbol CYT07 (see Note 14 Convertible Bond and Convertible loan notes, to the consolidated financial statements). On January 26, 2015, the bondholder meeting resolved to convert the outstanding bond into registered shares. Such resolution has been confirmed by the Superior Court Zurich on March 6, 2015 and is expected to become legally binding for all bond holders in May

18 Cytos Biotechnology Ltd Corporate Governance Overview of outstanding options1 on December 31, 2014, options granted to the Board of Directors (BoD) are marked accordingly (each option entitles the option holder to purchase one share): Year of grant Number of options outstanding Exercise price (CHF) Exercise period (years) , ,289 BoD , , , , ,000 BoD , , , ,000 BoD , , , , ,464, ,000 BoD ,040, Total 7,281,711 1) For further details please see Note 24, Share options, to the consolidated financial statements. 2) Options allocated to employees: options of individuals acting simultaneously as members of the Board of Directors and of the Executive Board are subsumed under options allocated to employees. 3) The option plan SOP 2014 was approved and granted by the Board of Directors in ) Options were granted to venbio Global Strategic Fund L.P. as part of the financing. The total 7,281,711 outstanding options represent CHF 728, nominal capital. 18

19 Cytos Biotechnology Ltd Corporate Governance Board of Directors (DCG 3) Members of the Board of Directors (DCG 3.1) Nomination & Name Corporate Year of First Elected Compensation Governance Audit Position, nationality birth elected until Committee Committee Committee Christian Itin, PhD Chairman & CEO, Switzerland John Berriman, MBA Vice Chairman, UK Joseph Anderson, PhD Member, UK Kurt von Emster, CFA Member, USA Former Members of the Board of Directors Arthur M. Krieg, MD* Vice Chairman, USA Paul Brooke* Member, USA Yamo Deniz, MD* Member, Sweden, USA * stepped down as board members effective Mai 31, 2014 Chairman Member Christian Itin Christian Itin, PhD, serves as of November 2012 as Cytos Chief Executive Officer and Chairman of the Board of Directors. Before joining Cytos, Dr. Itin was President and Chief Executive Officer of Micromet Inc., a former NASDAQ-listed biopharmaceutical company, with its headquarters in Rockville, MD, USA, and an R&D center in Munich, Germany, which was acquired in March 2012 by Amgen, Inc. for USD 1.16 billion. He spent 13 years with Micromet in a number of senior management roles, becoming CEO in Before joining Micromet in 1999, Dr. Itin co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA. He received a Diploma in biology and a PhD in cell biology from Basel University, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at Stanford University School of Medicine, CA, USA. Dr. Itin serves as Chairman of Autolus Ltd. (London, UK) and as non-executive director of Kymab Ltd (Cambridge, UK) and Zyngenia Inc. (Gaithersburg, MD, USA). Christian Itin is a Swiss citizen and resident of Germany. 19

20 Cytos Biotechnology Ltd Corporate Governance John Berriman John Berriman, MBA, has been a member of the Board of Directors since May 2012 and was elected as its Vice Chairman in May He is the Chairman of the board of AIM-listed ReNeuron Group plc and Autifony Therapeutics Ltd; and a non-executive director of Autolus Ltd. He is a past Chairman of Heptares Therapeutics Ltd (sold to Sosei in February 2015) and Algeta ASA (sold to Bayer AG in 2014 and previously listed on the Oslo stock exchange). He was a member of the Board of Directors of NASDAQ-listed Micromet Inc. until its sale to Amgen in Previously he was a Director of Abingworth Management Ltd, an international investment group dedicated exclusively to the life sciences and healthcare sectors, where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA, many of which obtained listings on public stock exchanges. Before that, Mr. Berriman spent 14 years with Celltech Group plc and was an executive director on its Board when it listed on the London Stock Exchange in He has a degree in chemical engineering from the University of Cambridge, UK, and a Masters degree from the London Business School. He is a British citizen and a resident of the UK. Joseph Anderson Joseph Anderson, PhD, has been a member of the Board of Directors since May He is a Partner at Abingworth LLP, an international investment group dedicated to the life sciences and healthcare sectors. He leads private investments in public companies in the US and Europe. Dr. Anderson has more than 25 years experience as a portfolio manager and analyst in the pharmaceutical and bioscience sectors and he has founded and managed two healthcare funds, has been a Special Adviser to the UK Government and published more than 50 papers on research management. Before joining Abingworth in 2004, Dr. Anderson was Head of Global Healthcare Equities at First State Investments in London, part of the Commonwealth Bank of Australia. Prior to this, he was a pharmaceuticals analyst at Dresdner Kleinwort Benson, an investment bank. From 1990 to 1998, Dr. Anderson established and was Head of the Strategy Unit at The Wellcome Trust, one of the world s largest medical foundations. He has been a Non-executive Director of Algeta ASA (acquired by Bayer), Amarin Corp. (NASDAQ) and Epigenomics AG (Frankfurt). He is also a Director of Abingworth BioEquities Master Fund Limited, an offshore investment fund. Dr. Anderson has a BSc (First Class Hons.) and a PhD in Biochemistry. He is a British citizen and resident of the UK. Kurt von Emster Kurt von Emster, CFA has been a member of the Board of Directors since May He is a Partner at Abingworth LLP, an international investment group dedicated to the life sciences and healthcare sectors. He has been an institutional biotechnology and health care analyst and portfolio manager for over 25 years. Mr. von Emster s investment career started in 1989 at Franklin Templeton where he founded and managed several health and biotechnology funds in the 1990s, each achieving a 5-star Morningstar ranking. In 2001, Mr. von Emster became a General Partner at MPM Capital, a leading biotechnology private equity firm, and launched the MPM BioEquities Fund, a cross over public and private biotechnology hedge fund. He was the portfolio manager of this fund from inception in 2001 until his departure in In 2009, he co-founded venbio, a strategic life science investment firm and departed in January He is a member of the Board of Directors of Crispr Therapeutics and CymaBay Therapeutics Inc., a former member of the Board of Aurinia Pharmaceuticals, Somaxon Pharmaceuticals Inc. and Facet Biotech Corporation and a former Board observer of Acceleron Pharma. Mr. von Emster holds a BA from the University of California, Santa Barbara, and is a certified financial analyst. He is a US citizen and resident of the USA. Christian Itin is as CEO Member of the Executive Board. No other Board member is or has been member of the executive management or has a material business relationship with the Company. 20

July 23, 2015 FIRST HALF-YEAR REPORT 2015

July 23, 2015 FIRST HALF-YEAR REPORT 2015 July 23, 2015 FIRST HALF-YEAR REPORT 2015 as of June 30, 2015 Financial summary YTD* 2015 YTD* 2014 Revenue CHF million 4.5 0.5 Net operating costs CHF million (2.3) (16.5) Net income/(loss) CHF million

More information

September 30, 2014 FIRST HALF-YEAR REPORT 2014

September 30, 2014 FIRST HALF-YEAR REPORT 2014 September 30, 2014 FIRST HALF-YEAR REPORT 2014 as of June 30, 2014 Financial summary YTD* 2014 YTD* 2013 Revenue CHF million 0.5 0.5 Net operating costs CHF million (16.5) (10.5) Net loss CHF million (23.4)

More information

Articles of Association Swiss Life Holding Ltd

Articles of Association Swiss Life Holding Ltd Articles of Association Swiss Life Holding Ltd (Translation of the original text in German) I. Company name, object and registered office 1. Company name, legal form Under the corporate name Swiss Life

More information

ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106)

ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106) Unauthorised translation ARTICLES OF ASSOCIATION OF NEUROSEARCH A/S (CVR-no. 12546106) Name, registered office and objects Article 1. The name of the company is NeuroSearch A/S. Article 2. The objects

More information

ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106)

ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106) Unauthorised translation ARTICLES OF ASSOCIATION OF NEUROSEARCH A/S (CVR-no. 12546106) Name, registered office and objects Article 1. The name of the company is NeuroSearch A/S. Article 2. The objects

More information

Articles of Incorporation Zurich Insurance Group Ltd 2015

Articles of Incorporation Zurich Insurance Group Ltd 2015 Articles of Incorporation Zurich Insurance Group Ltd 2015 Translation of the Articles of Incorporation of Zurich Insurance Group Ltd, Switzerland This is a translation of the original German version. In

More information

Unauthorised translation ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106)

Unauthorised translation ARTICLES OF ASSOCIATION NEUROSEARCH A/S. (CVR-no. 12546106) Unauthorised translation ARTICLES OF ASSOCIATION OF NEUROSEARCH A/S (CVR-no. 12546106) Name, registered office and objects Article 1. The name of the company is NeuroSearch A/S. Article 2. The objects

More information

KAZAKHSTAN LAW ON JOINT STOCK COMPANIES

KAZAKHSTAN LAW ON JOINT STOCK COMPANIES KAZAKHSTAN LAW ON JOINT STOCK COMPANIES Important Disclaimer This does not constitute an official translation and the translator and the EBRD cannot be held responsible for any inaccuracy or omission in

More information

Convenience Translation the German version is the only legally binding version. Articles of Association. Linde Aktiengesellschaft.

Convenience Translation the German version is the only legally binding version. Articles of Association. Linde Aktiengesellschaft. Convenience Translation the German version is the only legally binding version Articles of Association Linde Aktiengesellschaft Munich 9 March 2015 Page 1 of 12 I. General Rules 1. Company Name, Principal

More information

Westmoreland Coal Company

Westmoreland Coal Company UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

More information

Articles of Association UBS Group AG (UBS Group SA) (UBS Group Inc.)

Articles of Association UBS Group AG (UBS Group SA) (UBS Group Inc.) Articles of Association UBS Group AG (UBS Group SA) (UBS Group Inc.) 5 February 06 The present text is a translation of the original German Articles of Association ( Statuten ) which constitute the definitive

More information

The Kroger Co. Board of Directors. Guidelines on Issues of Corporate Governance. (Rev. 5/11/15)

The Kroger Co. Board of Directors. Guidelines on Issues of Corporate Governance. (Rev. 5/11/15) The Kroger Co. Board of Directors Guidelines on Issues of Corporate Governance (Rev. 5/11/15) THE KROGER CO. BOARD OF DIRECTORS GUIDELINES ON ISSUES OF CORPORATE GOVERNANCE The Kroger Co. Board of Directors

More information

ARTICLES OF ASSOCIATION

ARTICLES OF ASSOCIATION MAÎTRE CHOCOLATIER SUISSE DEPUIS 845 GROUP I. COMPANY NAME, REGISTERED OFFICE, DURATION AND PURPOSE ARTICLE Under the corporate name Chocoladefabriken Lindt & Sprüngli AG exists a share company for an

More information

APPROVED at the General Meeting of Participants of GSM Kazakhstan OAO Kazakhtelecom LLP. CHARTER OF Kcell Joint Stock Company

APPROVED at the General Meeting of Participants of GSM Kazakhstan OAO Kazakhtelecom LLP. CHARTER OF Kcell Joint Stock Company APPROVED at the General Meeting of Participants of GSM Kazakhstan OAO Kazakhtelecom LLP Minutes No. Date: CHARTER OF Kcell Joint Stock Company 1. General Provisions 1. This Charter of the joint stock company

More information

HEALTH CARE REIT, INC. CORPORATE GOVERNANCE GUIDELINES

HEALTH CARE REIT, INC. CORPORATE GOVERNANCE GUIDELINES HEALTH CARE REIT, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the Board ) of Health Care REIT, Inc. ( HCN ) has adopted these guidelines to promote the effective functioning of the Board

More information

Condensed Consolidated Interim Financial Statements of Addex Therapeutics Ltd as at June 30, 2016 (unaudited)

Condensed Consolidated Interim Financial Statements of Addex Therapeutics Ltd as at June 30, 2016 (unaudited) Condensed Consolidated Interim Financial Statements of Addex Therapeutics Ltd as at June 30, 2016 (unaudited) Condensed Consolidated Interim Balance Sheets as at June 30, 2016 and December 31, 2015 (unaudited)

More information

Biotie Therapies Corp. 4.3.2014

Biotie Therapies Corp. 4.3.2014 1 Biotie Therapies Corp. Corporate Governance Statement 2013 2 CONTENTS 1. Corporate Governance Statement 2. Board of Directors 2.1. Board composition 2.2. The operation of the Board of Directors 2.3.

More information

Interim Financial Statements 2014

Interim Financial Statements 2014 Table of Contents FINANCIAL DISCUSSION FIRST HALF YEAR... 3 CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE SIX MONTHS ENDED 30 JUNE... 6 CONDENSED CONSOLIDATED

More information

Terms and Conditions of Issuance of Profit Participation Certificates (Terms and Conditions of Issuance of Genussscheine 2001)

Terms and Conditions of Issuance of Profit Participation Certificates (Terms and Conditions of Issuance of Genussscheine 2001) Terms and Conditions of Issuance of Profit Participation Certificates (Terms and Conditions of Issuance of Genussscheine 2001) 1 Issuance of Profit Participation Certificates ( PPCs ) The Articles of Association

More information

AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BEST BUY CO., INC. ARTICLE I NAME. The name of this corporation shall be Best Buy Co., Inc.

AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BEST BUY CO., INC. ARTICLE I NAME. The name of this corporation shall be Best Buy Co., Inc. AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BEST BUY CO., INC. ARTICLE I NAME The name of this corporation shall be Best Buy Co., Inc. ARTICLE II REGISTERED OFFICE; REGISTERED AGENT The registered

More information

Appendix 1 to notice to convene the EGM proposed new Articles of Association (the complete proposals with track changes)

Appendix 1 to notice to convene the EGM proposed new Articles of Association (the complete proposals with track changes) Appendix 1 to notice to convene the EGM proposed new Articles of Association (the complete proposals with track changes) ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218 Article 1 Article 1 1.1. 1.1

More information

Status of Capital Adequacy

Status of Capital Adequacy Capital Adequacy Ratio Highlights 204 Status of Consolidated Capital Adequacy of Mizuho Financial Group, Inc. 206 Scope of Consolidation 206 Consolidated Capital Adequacy Ratio 208 Risk-Based Capital 210

More information

ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218

ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218 ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218 Article 1 1.1 The Company's name is TORM A/S. 1.2 The Company also carries out business under the secondary names Aktieselskabet af 3. November 1986

More information

NEWMARKET GOLD INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS. For the Three and Six Months Ended June 30, 2015 and 2014

NEWMARKET GOLD INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS. For the Three and Six Months Ended June 30, 2015 and 2014 NEWMARKET GOLD INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Expressed in Canadian Dollars - Unaudited) NOTICE OF NO AUDITOR REVIEW Under National Instrument 51-102, Part 4, subsection 4.3(3)

More information

IDENTIFY THE CHANCES SHAPE THE FUTURE

IDENTIFY THE CHANCES SHAPE THE FUTURE Status: june 2015 Complete text of Memorandum and Articles of Association of DMG MORI Aktiengesellschaft Bielefeld IDENTIFY THE CHANCES SHAPE THE FUTURE 1 (1) The Company exists under the name DMG MORI

More information

CORPORATE GOVERNANCE PRINCIPLES ZEAL NETWORK SE. (as adopted by the Supervisory Board and Executive Board on 19 November 2014)

CORPORATE GOVERNANCE PRINCIPLES ZEAL NETWORK SE. (as adopted by the Supervisory Board and Executive Board on 19 November 2014) CORPORATE GOVERNANCE PRINCIPLES OF ZEAL NETWORK SE (as adopted by the Supervisory Board and Executive Board on 19 November 2014) FOREWORD ZEAL Network SE ("Company") transferred its registered office from

More information

RESTATED ARTICLES OF INCORPORATION OF CISCO SYSTEMS, INC., a California Corporation

RESTATED ARTICLES OF INCORPORATION OF CISCO SYSTEMS, INC., a California Corporation RESTATED ARTICLES OF INCORPORATION OF CISCO SYSTEMS, INC., a California Corporation The undersigned, John T. Chambers and Larry R. Carter, hereby certify that: ONE: They are the duly elected and acting

More information

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS PURPOSE The Audit Committee (the Audit Committee ) is appointed by the Board of Directors (the Board ) of NVIDIA Corporation, a Delaware corporation

More information

UBS AG (Registrant s Name)

UBS AG (Registrant s Name) Page of 27 6-K d730760d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 3a-6 OR 5d-6 UNDER THE SECURITIES

More information

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF EVERBANK FINANCIAL CORP

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF EVERBANK FINANCIAL CORP CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF EVERBANK FINANCIAL CORP 1 EverBank Financial Corp Charter of the Audit Committee I. PURPOSE OF THE COMMITTEE The purpose of the Audit Committee

More information

CALLING NOTICE FOR ANNUAL GENERAL MEETING. The annual general meeting in Storm Real Estate AS (the Company ) will be held at

CALLING NOTICE FOR ANNUAL GENERAL MEETING. The annual general meeting in Storm Real Estate AS (the Company ) will be held at To the shareholders in Storm Real Estate AS CALLING NOTICE FOR ANNUAL GENERAL MEETING The annual general meeting in Storm Real Estate AS (the Company ) will be held at Hotel Scandic, Parkveien 68, Oslo

More information

EDISON INTERNATIONAL CORPORATE GOVERNANCE GUIDELINES. Adopted by the Board of Directors. February 26, 2015

EDISON INTERNATIONAL CORPORATE GOVERNANCE GUIDELINES. Adopted by the Board of Directors. February 26, 2015 EDISON INTERNATIONAL CORPORATE GOVERNANCE GUIDELINES Adopted by the Board of Directors February 26, 2015 These Corporate Governance Guidelines reflect current policies of the Board of Directors for the

More information

The board of directors proposal regarding a directed issue of series C

The board of directors proposal regarding a directed issue of series C The board of directors proposal regarding performance based, longterm share program for 2009 comprising proposal regarding a directed issue of series C shares and proposal regarding authorization for the

More information

Articles and Memorandum of Association - English convenience translation -

Articles and Memorandum of Association - English convenience translation - Articles and Memorandum of Association - English convenience translation - as of April 08, 2015 This is the convenience translation of the German original version of the Articles and Memorandum of Association

More information

FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS MAY 11, 2015

FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS MAY 11, 2015 FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC I. PURPOSE OF THE COMMITTEE CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS MAY 11, 2015 The purpose of the Audit Committee (the Committee

More information

DECISION NO (94/R) OF 2005 CONCERNING THE LISTING OF DEBT SECURITIES

DECISION NO (94/R) OF 2005 CONCERNING THE LISTING OF DEBT SECURITIES DECISION NO (94/R) OF 2005 CONCERNING THE LISTING OF DEBT SECURITIES The Chairman of the Board of Directors of the Stocks and Commodities Authority has, After pursuing the provisions of Federal Law No.

More information

COMPOSITE OF AMENDED RESTATED CERTIFICATE OF INCORPORATION AMERICAN ELECTRIC POWER COMPANY, INC. Under Section 807 of the Business Corporation Law

COMPOSITE OF AMENDED RESTATED CERTIFICATE OF INCORPORATION AMERICAN ELECTRIC POWER COMPANY, INC. Under Section 807 of the Business Corporation Law COMPOSITE OF AMENDED RESTATED CERTIFICATE OF INCORPORATION OF AMERICAN ELECTRIC POWER COMPANY, INC. Under Section 807 of the Business Corporation Law As filed with the Department of State of the State

More information

Stolt-Nielsen Limited

Stolt-Nielsen Limited Stolt-Nielsen Limited Relevant Legislation and Codes of Practice for Corporate Governance Stolt-Nielsen Limited s ( SNL or the Company ) Corporate Governance addresses the interaction between SNL s shareholders,

More information

Memorandum and Articles of Association

Memorandum and Articles of Association Aareal Bank AG Wiesbaden Memorandum and Articles of Association In accordance with the resolutions passed by the General Meeting on 20 May 2015 (version lodged with the Commercial Register of the Wiesbaden

More information

Shareholders Agreement

Shareholders Agreement Shareholders Agreement This Shareholders Agreement is made on..by and between: 1. Mr. with residence at.., (hereinafter X ); 2. Mr. with residence at (hereinafter Y ); 3.. nv, a Belgian naamloze vennootschap,

More information

Sixth Amended and Restated Certificate of Incorporation of Visa Inc.

Sixth Amended and Restated Certificate of Incorporation of Visa Inc. Sixth Amended and Restated Certificate of Incorporation of Visa Inc. Visa Inc., a corporation organized and existing under the laws of the State of Delaware (the Corporation ), hereby certifies that: 1.

More information

CORPORATE GOVERNANCE CODE

CORPORATE GOVERNANCE CODE Contents PART I. THE BOARD OF DIRECTORS AND ITS MEMBERS... 2 PART II. OPERATIONAL RISK MANAGEMENT... 5 PART III. INTERNAL AUDIT FUNCTION... 6 PART IV. INVESTOR RELATIONS... 8 PART V. REMUNERATIONS... 10

More information

QIAGEN N.V. Corporate Governance

QIAGEN N.V. Corporate Governance 118 QIAGEN N.V. Corporate Governance Corporate Governance 119 Corporate Governance Decl ar ation of Com pliance of Q IAGEN N.V. regarding the Ger m an Corpor ate Governance Code In QIAGEN s 2001 Annual

More information

Convenience Translation. The German language version shall prevail in the event of any dispute or ambiguity. Rocket Internet SE Berlin

Convenience Translation. The German language version shall prevail in the event of any dispute or ambiguity. Rocket Internet SE Berlin Convenience Translation. The German language version shall prevail in the event of any dispute or ambiguity. Rocket Internet SE Berlin Securities Identification Number (WKN): A12UKK ISIN: DE000A12UKK6

More information

ARTICLES OF ASSOCIATION

ARTICLES OF ASSOCIATION ARTICLES OF ASSOCIATION OF STRÖER MEDIA SE I. GENERAL CONDITIONS ARTICLE 1 COMPANY, REGISTERED OFFICE AND TERM (1) The Company has the name Ströer Media SE. (2) The Company s registered office is in Cologne.

More information

The Rubicon Project, Inc. Corporate Governance Guidelines

The Rubicon Project, Inc. Corporate Governance Guidelines The Rubicon Project, Inc. Corporate Governance Guidelines These Corporate Governance Guidelines reflect the corporate governance practices established by the Board of Directors (the Board ) of The Rubicon

More information

ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218

ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218 ARTICLES OF ASSOCIATION of TORM A/S CVR no. 22460218 Article 1 1.1 The Company's name is TORM A/S. 1.2 The Company also carries out business under the secondary names Aktieselskabet af 3. November 1986

More information

7. (a) Place and Method of Offering / (b) Offer price of the Bonds:

7. (a) Place and Method of Offering / (b) Offer price of the Bonds: FOR RELEASE: September 2, 2004 Notice Concerning Issuance of Euro Yen Convertible Bonds due 2011 (convertible bonds type - bonds with stock acquisition rights, tenkanshasaigata shinkabu yoyakuken-tsuki

More information

TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES

TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES The Board of Directors of Tenet Healthcare Corporation, acting on the recommendation of its Nominating and Corporate Governance Committee, has

More information

WSP GLOBAL INC. AMENDED AND RESTATED CORPORATE GOVERNANCE GUIDELINES

WSP GLOBAL INC. AMENDED AND RESTATED CORPORATE GOVERNANCE GUIDELINES WSP GLOBAL INC. AMENDED AND RESTATED CORPORATE GOVERNANCE GUIDELINES MARCH 2015 TABLE OF CONTENTS 3 WSP GLOBAL INC. 3 INTRODUCTION 3 A.BOARD RESPONSIBILITIES 3 B. EXPECTATIONS OF DIRECTORS 4 C. BOARD ORGANIZATION

More information

JAZZ PHARMACEUTICALS PLC CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

JAZZ PHARMACEUTICALS PLC CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS JAZZ PHARMACEUTICALS PLC CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS PURPOSE AND POLICY The purpose of the Audit Committee (the Committee ) shall be to act on behalf of the Board of Directors

More information

Articles of Association. SQS Software Quality Systems AG

Articles of Association. SQS Software Quality Systems AG Status: 10 November 2015 Articles of Association of SQS Software Quality Systems AG III. General Provisions 1 Name, Registered Office, Fiscal Year 1. The name of the company is SQS Software Quality Systems

More information

German Corporate Governance Code. (as amended on June 24, 2014 with decisions from the plenary meeting of June 24, 2014)

German Corporate Governance Code. (as amended on June 24, 2014 with decisions from the plenary meeting of June 24, 2014) (as amended on June 24, 2014 with decisions from the plenary meeting of June 24, 2014) 1 Foreword 1 The German Corporate Governance Code (the "Code") presents essential statutory regulations for the management

More information

DEMERGER PLAN. concerning the partial demerger of. Digia Plc

DEMERGER PLAN. concerning the partial demerger of. Digia Plc 1 DEMERGER PLAN concerning the partial demerger of Digia Plc 1 Demerger Digia Plc (hereinafter the Demerging Company ) will be split such that part of its assets and liabilities will be transferred to

More information

BMW Group. Corporate Governance Code. Principles of Corporate Governance.

BMW Group. Corporate Governance Code. Principles of Corporate Governance. BMW Group Corporate Governance Code. Principles of Corporate Governance. - 2 - Contents Page Introduction 3 1. Shareholders and Annual General Meeting of BMW AG 5 1.1 Shareholders of BMW AG 5 1.2 The Annual

More information

ADVANCED DRAINAGE SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES

ADVANCED DRAINAGE SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES ADVANCED DRAINAGE SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES These Corporate Governance Guidelines have been adopted by the Board of Directors (the Board ) of Advanced Drainage Systems, Inc. (the Company

More information

CHESAPEAKE ENERGY CORPORATION CORPORATE GOVERNANCE PRINCIPLES. (Amended as of June 13, 2014)

CHESAPEAKE ENERGY CORPORATION CORPORATE GOVERNANCE PRINCIPLES. (Amended as of June 13, 2014) CHESAPEAKE ENERGY CORPORATION CORPORATE GOVERNANCE PRINCIPLES (Amended as of June 13, 2014) 1. The Role of the Board of Directors The Board of Directors is responsible for the oversight of the Corporation

More information

HUMAN RESOURCES COMMITTEE OF THE BOARD OF DIRECTORS OF THE TORONTO-DOMINION BANK CHARTER

HUMAN RESOURCES COMMITTEE OF THE BOARD OF DIRECTORS OF THE TORONTO-DOMINION BANK CHARTER HUMAN RESOURCES COMMITTEE OF THE BOARD OF DIRECTORS OF THE TORONTO-DOMINION BANK Main Responsibilities: CHARTER ~~ Responsible for Management s Performance Evaluation, Compensation and Succession Planning

More information

NOTICE OF EXTRAORDINARY GENERAL MEETING IN BONG AB (publ)

NOTICE OF EXTRAORDINARY GENERAL MEETING IN BONG AB (publ) This is a non-official translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail. NOTICE OF EXTRAORDINARY

More information

LONDON STOCK EXCHANGE HIGH GROWTH SEGMENT RULEBOOK 27 March 2013

LONDON STOCK EXCHANGE HIGH GROWTH SEGMENT RULEBOOK 27 March 2013 LONDON STOCK EXCHANGE HIGH GROWTH SEGMENT RULEBOOK 27 March 2013 Contents INTRODUCTION... 2 SECTION A ADMISSION... 3 A1: Eligibility for admission... 3 A2: Procedure for admission... 4 SECTION B CONTINUING

More information

HALOGEN SOFTWARE INC. AUDIT COMMITTEE CHARTER. oversee the qualifications and independence of the independent auditor;

HALOGEN SOFTWARE INC. AUDIT COMMITTEE CHARTER. oversee the qualifications and independence of the independent auditor; HALOGEN SOFTWARE INC. AUDIT COMMITTEE CHARTER PURPOSE The Audit Committee is a standing committee appointed by the Board of Directors of Halogen Software Inc. The Committee is established to fulfill applicable

More information

WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES

WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES The following Corporate Governance Guidelines have been adopted by the Board of Directors (the Board ) of Wal-Mart Stores, Inc. (the Company ) to assist

More information

Corporate Governance Regulations

Corporate Governance Regulations Corporate Governance Regulations Contents Part 1: Preliminary Provisions Article 1: Preamble... Article 2: Definitions... Part 2: Rights of Shareholders and the General Assembly Article 3: General Rights

More information

Financial Report Annual Financial Report 2015

Financial Report Annual Financial Report 2015 Deutsche Postbank Funding Trust IV (a statutory trust formed under the Delaware Statutory Trust Act with its principal place of business in New York, NY, U.S.A.) Financial Report Annual Financial Report

More information

Corporate Governance Charter

Corporate Governance Charter BHF Kleinwort Benson Group SA Public limited liability company Avenue Louise 326 1050 Brussels RLE n 0866.015.010 Corporate Governance Charter Last amended as of 24 March 2015 Contents 1 Board of Directors...

More information

Invitation to the Annual General Meeting of shareholders of Betsson AB (publ)

Invitation to the Annual General Meeting of shareholders of Betsson AB (publ) APRIL 9 2015 Invitation to the Annual General Meeting of shareholders of Betsson AB (publ) The shareholders of Betsson AB (publ) (the Company ), are hereby invited to the Annual General Meeting of shareholders

More information

CMVM Regulation No. 4/2013 Corporate Governance

CMVM Regulation No. 4/2013 Corporate Governance CMVM Regulation No. 4/2013 Corporate Governance The Portuguese corporate governance framework is at present predominantly structured according to a model based on the CMVM regulation imposing on issuers

More information

COMPANY LAW OF MONGOLIA CHAPTER 1 GENERAL PROVISIONS

COMPANY LAW OF MONGOLIA CHAPTER 1 GENERAL PROVISIONS COMPANY LAW OF MONGOLIA CHAPTER 1 GENERAL PROVISIONS Article 1. Purpose of the Law 97.1. The purpose of this Law is to regulate the establishment, registration and reorganization of a company, its management

More information

Corporate Governance Code for Shareholding Companies Listed on the Amman Stock Exchange

Corporate Governance Code for Shareholding Companies Listed on the Amman Stock Exchange Corporate Governance Code for Shareholding Companies Listed on the Amman Stock Exchange CONTENTS Topic Page Preamble 3 Chapter One: Definitions 5 Chapter Two: The Board of Directors of the Shareholding

More information

A R T I C L E S O F A S S O C I A T I O N X I N G AG XING AG

A R T I C L E S O F A S S O C I A T I O N X I N G AG XING AG A R T I C L E S O F A S S O C I A T I O N OF X I N G AG 1. Name and place of incorporation of the Company 1.1. The name of the Company is: XING AG 1.2. The place of incorporation of the Company is Hamburg.

More information

AMENDED BY-LAWS OF STEELCASE INC. Amended as of: April 17, 2014

AMENDED BY-LAWS OF STEELCASE INC. Amended as of: April 17, 2014 AMENDED BY-LAWS OF STEELCASE INC. Amended as of: April 17, 2014 ARTICLE I Offices SECTION 1.01. Offices. The corporation may have offices at such places both within and without the State of Michigan as

More information

Algeta includes a Corporate Governance review in its annual report and has implemented a set of ethical guidelines.

Algeta includes a Corporate Governance review in its annual report and has implemented a set of ethical guidelines. Corporate governance principles and review As a Norwegian public limited liability company, Algeta is subject to the regulation of the Public Limited Liability Companies Act of 1997, as amended (the Act

More information

ARTICLES OF INCORPORATION. Miba Aktiengesellschaft. I. General provisions. Section 1 Name and seat of the company

ARTICLES OF INCORPORATION. Miba Aktiengesellschaft. I. General provisions. Section 1 Name and seat of the company ARTICLES OF INCORPORATION of Miba Aktiengesellschaft I. General provisions Section 1 Name and seat of the company (1) The name of the company is Miba Aktiengesellschaft (2) The company is based in Laakirchen,

More information

GREAT PLAINS ENERGY INCORPORATED BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES. Amended: December 9, 2014

GREAT PLAINS ENERGY INCORPORATED BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES. Amended: December 9, 2014 GREAT PLAINS ENERGY INCORPORATED BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES Amended: December 9, 2014 Introduction The Board of Directors (the Board ) of Great Plains Energy Incorporated (the Company

More information

Immune Therapeutics. Corporate Governance Guidelines.

Immune Therapeutics. Corporate Governance Guidelines. Immune Therapeutics Corporate Governance Guidelines The Board of Directors has adopted these Guidelines in order to reflect the Company s commitment to good corporate governance. The Board believes that

More information

SBERBANK OF RUSSIA. Regulations on Sberbank Supervisory Board Committees

SBERBANK OF RUSSIA. Regulations on Sberbank Supervisory Board Committees SBERBANK OF RUSSIA APPROVED by Sberbank s Supervisory Board Minutes No 51, dated November 14, 2014 Regulations on Sberbank Supervisory Board Committees Moscow, 2014 Table of contents 1. General... 3 2.

More information

Rolls Royce s Corporate Governance ADOPTED BY RESOLUTION OF THE BOARD OF ROLLS ROYCE HOLDINGS PLC ON 16 JANUARY 2015

Rolls Royce s Corporate Governance ADOPTED BY RESOLUTION OF THE BOARD OF ROLLS ROYCE HOLDINGS PLC ON 16 JANUARY 2015 Rolls Royce s Corporate Governance ADOPTED BY RESOLUTION OF THE BOARD OF ROLLS ROYCE HOLDINGS PLC ON 16 JANUARY 2015 Contents INTRODUCTION 2 THE BOARD 3 ROLE OF THE BOARD 5 TERMS OF REFERENCE OF THE NOMINATIONS

More information

RESTATED CERTIFICATE OF INCORPORATION OF BECTON, DICKINSON AND COMPANY AS OF JANUARY 29, 2013

RESTATED CERTIFICATE OF INCORPORATION OF BECTON, DICKINSON AND COMPANY AS OF JANUARY 29, 2013 RESTATED CERTIFICATE OF INCORPORATION OF BECTON, DICKINSON AND COMPANY AS OF JANUARY 29, 2013 Becton, Dickinson and Company, a corporation organized and existing under the laws of the State of New Jersey,

More information

CORPORATE GOVERNANCE GUIDELINES OF THE HOME DEPOT, INC. BOARD OF DIRECTORS. (Effective February 28, 2013)

CORPORATE GOVERNANCE GUIDELINES OF THE HOME DEPOT, INC. BOARD OF DIRECTORS. (Effective February 28, 2013) CORPORATE GOVERNANCE GUIDELINES OF THE HOME DEPOT, INC. BOARD OF DIRECTORS (Effective February 28, 2013) 1. MISSION STATEMENT The Board of Directors (the Board ) of The Home Depot, Inc. (the Company )

More information

CORPORATE GOVERNANCE GUIDELINES. (Adopted as of June 2, 2014)

CORPORATE GOVERNANCE GUIDELINES. (Adopted as of June 2, 2014) CORPORATE GOVERNANCE GUIDELINES (Adopted as of June 2, 2014) The following corporate governance guidelines have been approved and adopted by the Board of Directors (the Board ) of Arista Networks, Inc.

More information

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AQUABOUNTY TECHNOLOG IES, INC.

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AQUABOUNTY TECHNOLOG IES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AQUABOUNTY TECHNOLOG IES, INC. AQUABOUNTY TECHNOLOGIES, INC., a corporation organized and existing under the laws of the state of Delaware (the Corporation

More information

QUANTUM MATERIALS CORP. AUDIT COMMITTEE CHARTER

QUANTUM MATERIALS CORP. AUDIT COMMITTEE CHARTER QUANTUM MATERIALS CORP. AUDIT COMMITTEE CHARTER Purpose The role of the Audit Committee is to oversee the accounting and financial reporting processes of the Company and the audits of the financial statements

More information

INTEGRATED SILICON SOLUTION, INC. CORPORATE GOVERNANCE PRINCIPLES. Effective January 9, 2015

INTEGRATED SILICON SOLUTION, INC. CORPORATE GOVERNANCE PRINCIPLES. Effective January 9, 2015 INTEGRATED SILICON SOLUTION, INC. CORPORATE GOVERNANCE PRINCIPLES Effective January 9, 2015 These principles have been adopted by the Board of Directors (the "Board") of Integrated Silicon Solution, Inc.

More information

VII. Consolidated financial statements Credit Suisse (Bank) 281 Report of the Group Auditors. 283 Consolidated statements of income

VII. Consolidated financial statements Credit Suisse (Bank) 281 Report of the Group Auditors. 283 Consolidated statements of income VII Consolidated financial statements Credit Suisse (Bank) 281 Report of the Group Auditors 283 Consolidated statements of income 284 Consolidated balance sheets 286 Statements of changes in shareholder

More information

German Corporate Governance Code

German Corporate Governance Code (as amended on May 26, 2010) Government Commission German Corporate Governance Code 1. Foreword 1 This German Corporate Governance Code (the "Code") presents essential statutory regulations for the management

More information

HUMAN RESOURCES & COMPENSATION COMMITTEE CHARTER

HUMAN RESOURCES & COMPENSATION COMMITTEE CHARTER HUMAN RESOURCES & COMPENSATION COMMITTEE CHARTER DATE OF ISSUE: VERSION NO.: 4 PROCEDURES: None North American Energy Partners Inc. HUMAN RESOURCES & COMPENSATION COMMITTEE CHARTER 1. PURPOSE The Board

More information

CERTIFICATE OF DESIGNATION OF TERMS OF NON-CUMULATIVE CONVERTIBLE SERIES 2004-1 PREFERRED STOCK

CERTIFICATE OF DESIGNATION OF TERMS OF NON-CUMULATIVE CONVERTIBLE SERIES 2004-1 PREFERRED STOCK CERTIFICATE OF DESIGNATION OF TERMS OF NON-CUMULATIVE CONVERTIBLE SERIES 2004-1 PREFERRED STOCK 1. Designation, Par Value and Number of Shares. The designation of the series of preferred stock of the Federal

More information

ALAMOS GOLD INC. AUDIT COMMITTEE CHARTER

ALAMOS GOLD INC. AUDIT COMMITTEE CHARTER ALAMOS GOLD INC. Organization AUDIT COMMITTEE CHARTER This charter governs the operations of the Audit Committee (the Committee ) of Alamos Gold Inc. (the Company ). The purpose, composition, responsibilities,

More information

On behalf of the Board of Directors of GF and of the Compensation Committee, I am pleased to present the 2014 Compensation

On behalf of the Board of Directors of GF and of the Compensation Committee, I am pleased to present the 2014 Compensation Compensation Report Introduction by the Chairman of the Compensation Committee Dear shareholder On behalf of the Board of Directors of GF and of the Compensation Committee, I am pleased to present the

More information

TRANSLATION ARTICLES OF ASSOCIATION. ALK-Abelló A/S (Company registration (CVR) no. 63 71 79 16) (the Company") March 20142016

TRANSLATION ARTICLES OF ASSOCIATION. ALK-Abelló A/S (Company registration (CVR) no. 63 71 79 16) (the Company) March 20142016 TRANSLATION ARTICLES OF ASSOCIATION of ALK-Abelló A/S (Company registration (CVR) no. 63 71 79 16) (the Company") March 20142016 1. Name 1.1 The name of the company is ALK-Abelló A/S. 1.2 The Company also

More information

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF TRIANGLE PETROLEUM CORPORATION AMENDED AND RESTATED AS OF JUNE 6, 2013

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF TRIANGLE PETROLEUM CORPORATION AMENDED AND RESTATED AS OF JUNE 6, 2013 CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF TRIANGLE PETROLEUM CORPORATION AMENDED AND RESTATED AS OF JUNE 6, 2013 I. PURPOSE OF THE COMMITTEE The purpose of the Audit Committee (the "Committee")

More information

OPEN JOINT STOCK COMPANY AGENCY FOR HOUSING MORTGAGE LENDING. Agency for Housing Mortgage Lending OJSC INFORMATION POLICY GUIDELINES.

OPEN JOINT STOCK COMPANY AGENCY FOR HOUSING MORTGAGE LENDING. Agency for Housing Mortgage Lending OJSC INFORMATION POLICY GUIDELINES. OPEN JOINT STOCK COMPANY AGENCY FOR HOUSING MORTGAGE LENDING APPROVED: by decision of the Supervisory Council (minutes No 09 of 21 December 2007) Agency for Housing Mortgage Lending OJSC INFORMATION POLICY

More information

ARTICLES OF ASSOCIATION BAVARIAN NORDIC A/S. CVR no. 16271187

ARTICLES OF ASSOCIATION BAVARIAN NORDIC A/S. CVR no. 16271187 DRAFT ARTICLES OF ASSOCIATION OF BAVARIAN NORDIC A/S ARTICLES OF ASSOCIATION of BAVARIAN NORDIC A/S CVR no. 16271187 NAME, OBJECTS OF THE COMPANY AND CORPORATE LANGUAGE Article 1 The name of the company

More information

AVON PRODUCTS, INC. CORPORATE GOVERNANCE GUIDELINES. As amended by the Board of Directors as of December 9, 2013

AVON PRODUCTS, INC. CORPORATE GOVERNANCE GUIDELINES. As amended by the Board of Directors as of December 9, 2013 I. Purpose of Guidelines AVON PRODUCTS, INC. CORPORATE GOVERNANCE GUIDELINES As amended by the Board of Directors as of December 9, 2013 These corporate governance guidelines are intended to set a proper

More information

CERTIFICATE OF DESIGNATION OF PREFERRED STOCK OF LIGHTING SCIENCE GROUP CORPORATION. To Be Designated Series B Preferred Stock

CERTIFICATE OF DESIGNATION OF PREFERRED STOCK OF LIGHTING SCIENCE GROUP CORPORATION. To Be Designated Series B Preferred Stock CERTIFICATE OF DESIGNATION OF PREFERRED STOCK OF LIGHTING SCIENCE GROUP CORPORATION To Be Designated Series B Preferred Stock Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware

More information

WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES

WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES WAL-MART STORES, INC. CORPORATE GOVERNANCE GUIDELINES The following Corporate Governance Guidelines have been adopted by the Board of Directors (the Board ) of Wal-Mart Stores, Inc. (the Company ) to assist

More information

CORPORATE GOVERNANCE CODE OF OPEN JOINT-STOCK COMPANY OIL COMPANY ROSNEFT

CORPORATE GOVERNANCE CODE OF OPEN JOINT-STOCK COMPANY OIL COMPANY ROSNEFT APPROVED BY Resolution of the Board of Directors Minutes No. 6 dated May 17, 2006 CORPORATE GOVERNANCE CODE OF OPEN JOINT-STOCK COMPANY OIL COMPANY ROSNEFT With amendments: No.1 (approved by the Board

More information

Invitation to the Ordinary Annual General Meeting 2015

Invitation to the Ordinary Annual General Meeting 2015 Invitation to the Ordinary Annual General Meeting 2015 The German Version of the Invitation to the Ordinary Annual General Meeting is the only legally binding version. The English translation is for convenience

More information

Coach, Inc. Corporate Governance Principles

Coach, Inc. Corporate Governance Principles Coach, Inc. Corporate Governance Principles The following principles have been approved by the Board of Directors and, along with the charters and protocols of the Board committees, provide the framework

More information